Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Treatment Strategies for Patients with Relapsed Acute Lymphoblastic Leukemia: Allogeneic Stem Cell Transplantation Is Effective without Prior Reinduction Chemotherapy.

Theis H. Terwey, MD, Gero Massenkeil, MD, Ingo Tamm, MD, Christoph Lutz, MD, Philipp Hemmati, MD, Stefan Neuburger, MD, Bernd Dorken, MD, Renate Arnold, MD

Blood (2006) 108 (11): 3004.

https://doi.org/10.1182/blood.V108.11.3004.3004

Published: 2006

Journal Articles

Survivin Is Negatively Regulated by Early Growth Response (Egr)-1 Transcription Factor in Acute Myeloid Leukemia.

Ingo Tamm, MD, Karin Schmelz, Ph.D., Bernd Dörken, M.D., Mandy Wagner, Ph.D.

Blood (2006) 108 (11): 1943.

https://doi.org/10.1182/blood.V108.11.1943.1943

Published: 2006

Journal Articles

No Impact of Adverse Karyotype on Outcome after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Lymphoblastic Leukemia.

Ingo Tamm, MD, Gero Massenkeil, M.D., Mandy Wagner, Ph.D., Theis Terwey, M.D., Christoph Lutz, M.D., Stefan Neuburger, M.D., Christiane Bommert, M.D., Bernd Dörken, M.D., Renate Arnold, M.D.

Blood (2006) 108 (11): 3152.

https://doi.org/10.1182/blood.V108.11.3152.3152

Published: 2006

Journal Articles

Decitabine: Where Is the Target?.

Ingo Tamm, MD, Nicole Sattler, PhD, Mandy Wagner, PhD, Michael Lübbert, MD, Philipp leCoutre, MD, Bernd Dörken, MD, Karin Schmelz, PhD

Blood (2005) 106 (11): 495.

https://doi.org/10.1182/blood.V106.11.495.495

Published: 2005

Journal Articles

Structural and Complex Chromosomal Aberrations Frequently Develop in Skin Fibroblasts after Allogeneic Stem Cell Transplantation.

Gero Massenkeil, MD, Petra Zschieschang, MD, Julia Pross, Ingo Tamm, MD, Stephan Neuburger, MD, Christoph Lutz, MD, Oliver Rosen, MD, Bernd Dörken, MD, Renate Arnold, MD

Blood (2005) 106 (11): 1118.

https://doi.org/10.1182/blood.V106.11.1118.1118

Published: 2005

Journal Articles

Reduced Intensity Conditioning in Acute Leukemias: Long Term Follow-Up Confirms Sustained Complete Remissions.

Gero Massenkeil, MD, Stefan Neuburger, MD, Ingo Tamm, MD, Christoph Lutz, MD, Marion Nagy, PhD, Philipp Le Coutre, MD, Bernd Doerken, MD, Renate Arnold, MD

Blood (2004) 104 (11): 5147.

https://doi.org/10.1182/blood.V104.11.5147.5147

Published: 2004

Journal Articles

Activity and Induction of Apoptosis of the Specific Tyrosine Kinase Inhibitor AMN 107 in bcr-abl + Cell Lines and in Imatinib Resistant Primary Cells from CML Patients.

Philipp Le Coutre, MD, Gökben Baskaynak, MD, Ingo Tamm, MD, Jörg Westermann, MD, Justus Duyster, MD, Malte v. Bonin, MD, Stefan Pursche, MD, Petra Mayer, MD, Paul Manley, Ph.D., Jürgen Mestan, Ph.D., Eberhard Schleyer, M.D., Bernd Dorken, M.D.

Blood (2004) 104 (11): 762.

https://doi.org/10.1182/blood.V104.11.762.762

Published: 2004

Journal Articles

Donor Lymphocyte Infusions to Prevent Relapse in Acute Leukemias after Allogenic Stem Cell Transplantation.

Christoph Lutz, MD, Marion Nagy, PhD, Ingo Tamm, MD, Stefan Neuburger, MD, Bernd Doerken, MD, Renate Arnold, MD, Gero Massenkeil, MD

Blood (2004) 104 (11): 1642.

https://doi.org/10.1182/blood.V104.11.1642.1642

Published: 2004

NARROW

Treatment Strategies for Patients with Relapsed Acute Lymphoblastic Leukemia: Allogeneic Stem Cell Transplantation Is Effective without Prior Reinduction Chemotherapy.

Survivin Is Negatively Regulated by Early Growth Response (Egr)-1 Transcription Factor in Acute Myeloid Leukemia.

No Impact of Adverse Karyotype on Outcome after Allogeneic Stem Cell Transplantation in Patients with High-Risk Acute Lymphoblastic Leukemia.

Decitabine: Where Is the Target?.

Structural and Complex Chromosomal Aberrations Frequently Develop in Skin Fibroblasts after Allogeneic Stem Cell Transplantation.

Reduced Intensity Conditioning in Acute Leukemias: Long Term Follow-Up Confirms Sustained Complete Remissions.

Activity and Induction of Apoptosis of the Specific Tyrosine Kinase Inhibitor AMN 107 in bcr-abl + Cell Lines and in Imatinib Resistant Primary Cells from CML Patients.

Donor Lymphocyte Infusions to Prevent Relapse in Acute Leukemias after Allogenic Stem Cell Transplantation.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only